Evidence map›Paper›PMID 34773801›Full record

ArticleDiagnostic microbiology and infectious disease2022

Importance of anti-SARS-CoV-2 assay antigenic composition as revealed by the results of the Belgian external quality assessment (EQA) scheme.

Alena Moerman, Kris Vernelen, Bernard China, Arnaud Capron, Dorien Van Den Bossche, Joachim Mariën, Kevin K Ariën, Jos Van Acker, Marie-Luce Delforge, Marijke Reynders and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic microbiology and infectious disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alena MoermanLaboratory of Medical Microbiology, Ghent University Hospital, Ghent, Belgium. Electronic address: alena.moerman@uzgent.be.
Kris VernelenExperts Committee EQA Infectious serology, Quality of Laboratories, Sciensano, Brussels, Belgium; Quality of Laboratories, Sciensano, Brussels, Belgium.
Bernard ChinaExperts Committee EQA Infectious serology, Quality of Laboratories, Sciensano, Brussels, Belgium; Quality of Laboratories, Sciensano, Brussels, Belgium.
Arnaud CapronExperts Committee EQA Infectious serology, Quality of Laboratories, Sciensano, Brussels, Belgium; Quality of Laboratories, Sciensano, Brussels, Belgium.
Dorien Van Den BosscheExperts Committee EQA Infectious serology, Quality of Laboratories, Sciensano, Brussels, Belgium; Institute of Tropical Medicine, Antwerp, Belgium.
Joachim MariënInstitute of Tropical Medicine, Antwerp, Belgium.
Kevin K AriënInstitute of Tropical Medicine, Antwerp, Belgium; University of Antwerp, Antwerp, Belgium.
Jos Van AckerExperts Committee EQA Infectious serology, Quality of Laboratories, Sciensano, Brussels, Belgium; Laboratory of Clinical Microbiology, AZ Sint-Lucas, Ghent, Belgium.
Marie-Luce DelforgeExperts Committee EQA Infectious serology, Quality of Laboratories, Sciensano, Brussels, Belgium; CUB-Hôpital Erasme, ULB, Brussels, Belgium.
Marijke ReyndersExperts Committee EQA Infectious serology, Quality of Laboratories, Sciensano, Brussels, Belgium; AZ St. Jan, Bruges-Ostend, Belgium.
An BoelExperts Committee EQA Infectious serology, Quality of Laboratories, Sciensano, Brussels, Belgium; Department of Medical Microbiology, OLVZ Aalst, Aalst, Belgium.
Melissa DepypereExperts Committee EQA Infectious serology, Quality of Laboratories, Sciensano, Brussels, Belgium; Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
Natasja Van GasseExperts Committee EQA Infectious serology, Quality of Laboratories, Sciensano, Brussels, Belgium; Hospital Network Antwerp, Antwerp, Belgium.
Sara VijgenExperts Committee EQA Infectious serology, Quality of Laboratories, Sciensano, Brussels, Belgium; Department of Laboratory Medicine, Jessa Hospital, Hasselt, Belgium.
Jonathan BraunerExperts Committee EQA Infectious serology, Quality of Laboratories, Sciensano, Brussels, Belgium; University Centre Tivoli, La Louvière, Belgium.
Barbara DujardinExperts Committee EQA Infectious serology, Quality of Laboratories, Sciensano, Brussels, Belgium; University Centre Tivoli, La Louvière, Belgium.
Elizaveta PadalkoLaboratory of Medical Microbiology, Ghent University Hospital, Ghent, Belgium; Experts Committee EQA Infectious serology, Quality of Laboratories, Sciensano, Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report on sample IS/17575 since it generated highly divergent results in the Belgian SARS-CoV-2 serology external quality assessment scheme. Sample IS/17575 was serum originating from a 30 years old male patient. 124 diagnostic laboratories analysed this sample. A total of 168 results was returned (including 5 doubles). Overall, 38 were positive. All tests against S1 were positive except the Euroimmun IgG ELISA and the Ortho clinical Diagnostics VITROS IgG CLIA. All tests against S1/S2 (Liaison, Diasorin) resulted in a signal above cutoff. Assays against RBD, mostly generate a negative result. An exception are the Wantai SARS-CoV-2 ELISA's. All tests targeting N protein were negative. The survey shows, when >6 months post-infection, assays targeting at least S1, and preferably S1 combined with S2, are the most sensitive. This finding accentuates the necessity of external quality assessment schedules and importance of antigenic composition of serologic SARS-CoV-2 assays.

Indexed as

AdultAntibodies, ViralAntigens, ViralBelgiumCoronavirus Nucleocapsid ProteinsCOVID-19COVID-19 Serological TestingDiagnostic Tests, RoutineEnzyme-Linked Immunosorbent AssayHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MMalePhosphoproteinsSARS-CoV-2Antibodies, ViralAntigens, ViralCoronavirus Nucleocapsid ProteinsImmunoglobulin AImmunoglobulin GImmunoglobulin Mnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2external quality assessment schemeNucleocapsid proteinreceptor-binding domainSARS-CoV-2serologySpike protein

Identifiers

PMID34773801
PMCPMC8503966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.